The cytochrome P450 (CYP)4F2 gene is known to influence mean coumarin dose. The aim of the present study was to undertake a meta-analysis at the individual patients level to capture the possible effect of ethnicity, gene-gene interaction, or other drugs on the association and to verify if inclusion of CYP4F2*3 variant into dosing algorithms improves the prediction of mean coumarin dose. We asked the authors of our previous meta-analysis (30 articles) and of 38 new articles retrieved by a systematic review to send us individual patients' data. The final collection consists of 15,754 patients split into a derivation and validation cohort. The CYP4F2*3 polymorphism was consistently associated with an increase in mean coumarin dose (+9% (95% confidence interval (CI) 7-10%), with a higher effect in women, in patients taking acenocoumarol, and in white patients. The inclusion of the CYP4F2*3 in dosing algorithms slightly improved the prediction of stable coumarin dose. New pharmacogenetic equations potentially useful for clinical practice were derived.

Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals / Danese, Elisa; Raimondi, Sara; Montagnana, Martina; Tagetti, Angela; Langaee, Taimour; Borgiani, Paola; Ciccacci, Cinzia; Carcas, Antonio J; Borobia, Alberto M; Tong, Hoi Y; Dávila-Fajardo, Cristina; Rodrigues Botton, Mariana; Bourgeois, Stephane; Deloukas, Panos; Caldwell, Michael D; Burmester, Jim K; Berg, Richard L; Cavallari, Larisa H; Drozda, Katarzyna; Huang, Min; Zhao, Li-Zi; Cen, Han-Jing; Gonzalez-Conejero, Rocio; Roldan, Vanessa; Nakamura, Yusuke; Mushiroda, Taisei; Gong, Inna Y; Kim, Richard B; Hirai, Keita; Itoh, Kunihiko; Isaza, Carlos; Beltrán, Leonardo; Jiménez-Varo, Enrique; Cañadas-Garre, Marisa; Giontella, Alice; Kringen, Marianne K; Haug, Kari Bente Foss; Gwak, Hye Sun; Lee, Kyung Eun; Minuz, Pietro; Lee, Ming Ta Michael; Lubitz, Steven A; Scott, Stuart; Mazzaccara, Cristina; Sacchetti, Lucia; Genç, Ece; Özer, Mahmut; Pathare, Anil; Krishnamoorthy, Rajagopal; Paldi, Andras; Siguret, Virginie; Loriot, Marie-Anne; Kutala, Vijay Kumar; Suarez-Kurtz, Guilherme; Perini, Jamila; Denny, Josh C; Ramirez, Andrea H; Mittal, Balraj; Rathore, Saurabh Singh; Sagreiya, Hersh; Altman, Russ; Shahin, Mohamed Hossam A; Khalifa, Sherief I; Limdi, Nita A; Rivers, Charles; Shendre, Aditi; Dillon, Chrisly; Suriapranata, Ivet M; Zhou, Hong-Hao; Tan, Sheng-Lan; Tatarunas, Vacis; Lesauskaite, Vaiva; Zhang, Yumao; Maitland-van der Zee, Anke H; Verhoef, Talitha I; de Boer, Anthonius; Taljaard, Monica; Zambon, Carlo Federico; Pengo, Vittorio; Zhang, Jieying Eunice; Pirmohamed, Munir; Johnson, Julie A; Fava, Cristiano. - In: CLINICAL PHARMACOLOGY & THERAPEUTICS. - ISSN 0009-9236. - 105:6(2019), pp. 1477-1491. [10.1002/cpt.1323]

Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals

Mazzaccara, Cristina;Sacchetti, Lucia;
2019

Abstract

The cytochrome P450 (CYP)4F2 gene is known to influence mean coumarin dose. The aim of the present study was to undertake a meta-analysis at the individual patients level to capture the possible effect of ethnicity, gene-gene interaction, or other drugs on the association and to verify if inclusion of CYP4F2*3 variant into dosing algorithms improves the prediction of mean coumarin dose. We asked the authors of our previous meta-analysis (30 articles) and of 38 new articles retrieved by a systematic review to send us individual patients' data. The final collection consists of 15,754 patients split into a derivation and validation cohort. The CYP4F2*3 polymorphism was consistently associated with an increase in mean coumarin dose (+9% (95% confidence interval (CI) 7-10%), with a higher effect in women, in patients taking acenocoumarol, and in white patients. The inclusion of the CYP4F2*3 in dosing algorithms slightly improved the prediction of stable coumarin dose. New pharmacogenetic equations potentially useful for clinical practice were derived.
2019
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals / Danese, Elisa; Raimondi, Sara; Montagnana, Martina; Tagetti, Angela; Langaee, Taimour; Borgiani, Paola; Ciccacci, Cinzia; Carcas, Antonio J; Borobia, Alberto M; Tong, Hoi Y; Dávila-Fajardo, Cristina; Rodrigues Botton, Mariana; Bourgeois, Stephane; Deloukas, Panos; Caldwell, Michael D; Burmester, Jim K; Berg, Richard L; Cavallari, Larisa H; Drozda, Katarzyna; Huang, Min; Zhao, Li-Zi; Cen, Han-Jing; Gonzalez-Conejero, Rocio; Roldan, Vanessa; Nakamura, Yusuke; Mushiroda, Taisei; Gong, Inna Y; Kim, Richard B; Hirai, Keita; Itoh, Kunihiko; Isaza, Carlos; Beltrán, Leonardo; Jiménez-Varo, Enrique; Cañadas-Garre, Marisa; Giontella, Alice; Kringen, Marianne K; Haug, Kari Bente Foss; Gwak, Hye Sun; Lee, Kyung Eun; Minuz, Pietro; Lee, Ming Ta Michael; Lubitz, Steven A; Scott, Stuart; Mazzaccara, Cristina; Sacchetti, Lucia; Genç, Ece; Özer, Mahmut; Pathare, Anil; Krishnamoorthy, Rajagopal; Paldi, Andras; Siguret, Virginie; Loriot, Marie-Anne; Kutala, Vijay Kumar; Suarez-Kurtz, Guilherme; Perini, Jamila; Denny, Josh C; Ramirez, Andrea H; Mittal, Balraj; Rathore, Saurabh Singh; Sagreiya, Hersh; Altman, Russ; Shahin, Mohamed Hossam A; Khalifa, Sherief I; Limdi, Nita A; Rivers, Charles; Shendre, Aditi; Dillon, Chrisly; Suriapranata, Ivet M; Zhou, Hong-Hao; Tan, Sheng-Lan; Tatarunas, Vacis; Lesauskaite, Vaiva; Zhang, Yumao; Maitland-van der Zee, Anke H; Verhoef, Talitha I; de Boer, Anthonius; Taljaard, Monica; Zambon, Carlo Federico; Pengo, Vittorio; Zhang, Jieying Eunice; Pirmohamed, Munir; Johnson, Julie A; Fava, Cristiano. - In: CLINICAL PHARMACOLOGY & THERAPEUTICS. - ISSN 0009-9236. - 105:6(2019), pp. 1477-1491. [10.1002/cpt.1323]
File in questo prodotto:
File Dimensione Formato  
Clinical_Pharmacology_&_Therapeutics 2019.pdf

accesso aperto

Descrizione: Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals
Tipologia: Documento in Post-print
Licenza: Dominio pubblico
Dimensione 374.24 kB
Formato Adobe PDF
374.24 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/778298
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 21
social impact